SCHEMBL30395175

SCHEMBL30395175

O=C(O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ REN P00797 2/20 0.39
▸ ACE P12821 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ F2 P00734 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ LTA4H P09960 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PEPD P12955 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ THPO P40225 1/20 0.39
▸ PMP22 Q01453 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ACE2 Q9BYF1 1/20 0.39
▸ CAPN1 P07384 2/20 0.38
▸ TRHR P34981 2/20 0.38
▸ OPRM1 P35372 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30445980 0.95 CAPN1 (0.41) RENCAPN1TRHROPRM1CTSB
SCHEMBL30116355 0.89 ACE (0.43) RENACEKDM4EF2LMNA
SCHEMBL30817465 0.88 ACE (0.52) RENACEKDM4EF2LMNA
SCHEMBL29380028 0.88 ACE (0.46) RENACEKDM4EF2LMNA
SCHEMBL30452849 0.85 ACE (0.43) RENACEKDM4EF2LMNA
SCHEMBL29397117 0.85 DPP4 (0.46) CAPN1CTSBMEN1KMT2A
SCHEMBL29408003 0.84 DPP4 (0.45) ACEMEN1KMT2A
SCHEMBL29765176 0.84 CAPN1 (0.47) RENACEKDM4EF2LMNA
SCHEMBL32681290 0.84 OPRM1 (0.48) RENACEF2OPRM1
SCHEMBL30395259 0.84 ACE (0.48) RENACEKDM4EF2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158117-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF HYPERLIPIDEMIA COMPRISING TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF AND METHOD USING THE SAME HANMI PHARM. CO., LTD. (KR) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158117-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF HYPERLIPIDEMIA COMPRISING TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF AND METHOD USING THE SAME GLP1R, GIPR, GCGR REN 1057/4885ACE 2489/4885KDM4E 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback